This trial is evaluating whether therapeutic extended lymphadenectomy will improve 1 primary outcome and 2 secondary outcomes in patients with Urinary Bladder Cancer. Measurement will happen over the course of Up to 6 years from date of Step 2 Registration.
This trial requires 658 total participants across 2 different treatment groups
This trial involves 2 different treatments. Therapeutic Extended Lymphadenectomy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"The risk factors and underlying mechanisms for bladder cancer are complex and multifactorial, resulting from the interconnection of environmental exposures, genetic susceptibility, and the epigenetic profile at the cellular level. Further studies are warranted." - Anonymous Online Contributor
"This article describes the incidence of urinary [bladder cancer](https://www.withpower.com/clinical-trials/bladder-cancer) in the United States. The data show the incidence of urinary bladder cancer to be 0.4 percent of all new cancer cases in the USA every year. The 5-year survival rate of urinary bladder cancer is 75.3%. The incidence of urinary bladder cancer per 1,000,000 was 7.8. Urinary bladder cancer has the highest mortality of any type of cancer in the United States. The overall 5-year survival rate for urinary bladder cancer is 27.4%. A study done in Japan found that the incidence rate of urinary bladder cancer per million people per year is 7.7. The 5-year survival rate in Japan is 74.3%." - Anonymous Online Contributor
"There are significant number of alternative therapies that are used to treat bladder cancer. However, the best of the alternative therapies has not been proven to be effective." - Anonymous Online Contributor
"The urinary bladder is the first part of the urinary tract affected by cancer in children and adolescents. The most common type of urinary bladder cancer is transitional cell carcinoma, a malignancy of bladder cells. A number of factors are involved in the development and progression of bladder cancer." - Anonymous Online Contributor
"The most frequent symptom of bladder cancer is hematuria (blood in the urine), followed by urgency, incontinence and dysuria. There is also a correlation between these symptoms and bladder mass. The symptom of hematochezia (blood in stool), often seen in other gastrointestinal diseases can also be a symptom of bladder cancer. However, it is not an indispensable sign." - Anonymous Online Contributor
"Urinary [bladder cancer](https://www.withpower.com/clinical-trials/bladder-cancer) cannot be cured. Despite a considerable number of advanced cancer patients having undergone treatment, over half of those patients will have a local recurrence at a median of 3 and 6 years, respectively. Although the best possible treatment cannot be guaranteed, the current data indicate that some patients can live normal lives for years following treatment." - Anonymous Online Contributor
"Extended lymphadenectomy has long been assumed to have a therapeutic role in localized patients with T3 urothelial carcinoma of the urinary bladder; this assumption has not been validated by good-quality data." - Anonymous Online Contributor
"We have established that complete lymphadenectomy is feasible on a large percentage of patients having radical cystectomy. This will help improving survival of [bladder cancer](https://www.withpower.com/clinical-trials/bladder-cancer) patients, as complete removal of the lymphatic region that carries the metastatic cancers increases the efficacy of the cytotoxic therapy." - Anonymous Online Contributor
"Urinary bladder cancer treatment is still largely based on its TNM staging, and there have been no new studies and interventions since 2005. Although there has been more research over time, bladder cancer remains unchanged as a devastating disease. More effort needs to be put into increasing bladder cancer screening, and developing innovative treatment options." - Anonymous Online Contributor
"Lymphadenectomy +/- chemotherapy +/- hIL-2 +/- autologous stem cell transplantation may be used in patients with stage IIIB renal cell carcinoma. Patients with T3 bladder cancer should also undergo radical cystectomy +/- hIL-2 +/- autologous stem cell transplantation." - Anonymous Online Contributor
"To our knowledge, this is the first comprehensive study in the literature to compare the treatment result of therapeutic extended lymphadenectomy with those of conventional and modified lymphadenectomy in patients with bladder cancer. No statistically significant difference in PFS and OS were observed between treatment groups; however, more patients experienced an increased incidence of postoperative infection, thromboembolism, urinary incontinence, and urinary retention. A larger study is warranted to further investigate this finding." - Anonymous Online Contributor
"Urinary bladder cancer is found in only five to ten persons in every 1 million. Most bladder cancers are non-muscle-invasive and can be detected in the early stages. The probability of developing bladder cancer is about one in twenty for men and one in sixty for women at 85 years of age." - Anonymous Online Contributor